Zilretta, an innovative formulation for managing osteoarthritis (OA) pain, has transformed the way extended-release corticosteroids are delivered to patients. This unique formulation uses PLGA (Poly(lactic-co-glycolic acid)) as a critical excipient, enabling a sustained release of the active ingredient for long-lasting pain relief.
What is Zilretta?
Zilretta is an extended-release injectable corticosteroid approved for the treatment of osteoarthritis-related knee pain. Unlike traditional corticosteroid injections, which provide short-term relief, Zilretta offers sustained pain management over weeks, enhancing patient outcomes and reducing the need for frequent interventions.
The key to Zilretta’s prolonged efficacy lies in its use of microsphere technology, enabled by PLGA 75:25. This biopolymer allows for controlled degradation and release of the corticosteroid into the affected joint, minimizing systemic side effects and maximizing local therapeutic impact.
Why PLGA 75:25 is Crucial for Zilretta
PLGA 75:25 is a copolymer consisting of 75% lactic acid and 25% glycolic acid. It is widely recognized for its biocompatibility, biodegradability, and ability to modulate drug release rates. The selection of PLGA 75:25 for Zilretta is driven by the following key properties:
- Controlled Degradation: The 75:25 ratio balances hydrophobicity and hydrophilicity, ensuring an optimal degradation timeline that aligns with the therapeutic needs of extended drug release.
- Microsphere Formation: PLGA 75:25 is ideal for creating uniform, stable microspheres that encapsulate the corticosteroid, enabling precise dosing and sustained release.
- Safety Profile: As a US FDA-approved polymer, PLGA 75:25 meets stringent safety standards, ensuring patient safety when used in injectable formulations like Zilretta.
Applications of PLGA in Drug Delivery
Beyond Zilretta, PLGA has established itself as a cornerstone in modern drug delivery systems, particularly for:
- Cancer Therapeutics: Delivering chemotherapy agents with minimal side effects.
- Vaccines: Enhancing the stability and release of antigens.
- Ophthalmic Treatments: Prolonging the effect of intraocular drugs.
Nomisma Healthcare’s Role in Advancing PLGA Applications
At Nomisma Healthcare, we specialize in the production of high-quality biopolymers, including PLGA, tailored for advanced pharmaceutical applications. Our PLGA 75:25 is manufactured to meet the rigorous demands of injectable drug delivery systems.
Why Choose Nomisma PLGA?
- Customizable Ratios: We offer precise control over lactide-to-glycolide ratios to suit specific drug release requirements.
- Pharmaceutical-Grade Quality: Our polymers comply with international regulatory standards, ensuring their safety and efficacy in therapeutic applications.
- Expert Support: With a dedicated team of scientists and technical experts, we collaborate with pharmaceutical companies to develop cutting-edge solutions.
Partner with Nomisma Healthcare
If you are developing innovative therapeutics like Zilretta or exploring other drug delivery systems, Nomisma Healthcare is your trusted partner for premium-grade PLGA. Our expertise and commitment to quality make us the ideal choice for your polymer needs.
Reach out to us at www.nomismahealthcare.com today to learn more about how our biopolymers can enhance your formulations and drive therapeutic innovation.